+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
1269440-17-6,MFCD25976758
Catalog No.:AA000WCF

1269440-17-6 | Lgx818

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥98%
in stock  
$100.00   $70.00
- +
5mg
98%
in stock  
$132.00   $93.00
- +
25mg
98%
in stock  
$339.00   $237.00
- +
100mg
98%
in stock  
$902.00   $632.00
- +
250mg
95%
in stock  
$1,635.00   $1,144.00
- +
1g
98%
in stock  
$3,124.00   $2,187.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA000WCF
Chemical Name:
Lgx818
CAS Number:
1269440-17-6
Molecular Formula:
C22H27ClFN7O4S
Molecular Weight:
540.0107
MDL Number:
MFCD25976758
SMILES:
COC(=O)N[C@H](CNc1nccc(n1)c1cn(nc1c1cc(Cl)cc(c1F)NS(=O)(=O)C)C(C)C)C
Properties
Computed Properties
 
Complexity:
836  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
36  
Hydrogen Bond Acceptor Count:
10  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0  
Rotatable Bond Count:
10  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
2.7  

Downstream Synthesis Route

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1Locationinpatent:Page/Pagecolumn58-59

[1]Patent:WO2011/25927,2011,A1

[2]Patent:WO2011/25927,2011,A1

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[2]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[3]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[4]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

Literature

Title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Journal: The Lancet. Oncology 20180501

Title: Compounds and compositions as protein kinase inhibitors . Patent WO 2011025927 A1

Title: Li Z, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 1269440-17-6
Building Blocks
More >
Tags:1269440-17-6 Molecular Formula|1269440-17-6 MDL|1269440-17-6 SMILES|1269440-17-6 Lgx818
Catalog No.: AA000WCF
1269440-17-6,MFCD25976758
1269440-17-6 | Lgx818
Pack Size： 1mg
Purity： ≥98%
in stock
$100.00 $70.00
Pack Size： 5mg
Purity： 98%
in stock
$132.00 $93.00
Pack Size： 25mg
Purity： 98%
in stock
$339.00 $237.00
Pack Size： 100mg
Purity： 98%
in stock
$902.00 $632.00
Pack Size： 250mg
Purity： 95%
in stock
$1,635.00 $1,144.00
Pack Size： 1g
Purity： 98%
in stock
$3,124.00 $2,187.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA000WCF
Chemical Name: Lgx818
CAS Number: 1269440-17-6
Molecular Formula: C22H27ClFN7O4S
Molecular Weight: 540.0107
MDL Number: MFCD25976758
SMILES: COC(=O)N[C@H](CNc1nccc(n1)c1cn(nc1c1cc(Cl)cc(c1F)NS(=O)(=O)C)C(C)C)C
Properties
Complexity: 836  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 1  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 36  
Hydrogen Bond Acceptor Count: 10  
Hydrogen Bond Donor Count: 3  
Isotope Atom Count: 0  
Rotatable Bond Count: 10  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 2.7  
Downstream Synthesis Route
1269440-76-7    124-63-0    1269440-17-6 

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1Locationinpatent:Page/Pagecolumn58-59

1996-30-1    1269440-17-6 

[1]Patent:WO2011/25927,2011,A1

[2]Patent:WO2011/25927,2011,A1

89897-29-0    1269440-17-6 

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[2]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[3]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

[4]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

1269232-93-0    1269440-17-6 

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

1269232-94-1    1269440-17-6 

[1]CurrentPatentAssignee:PFIZERINC-WO2011/25927,2011,A1

Literature fold

Title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Journal: The Lancet. Oncology20180501

Title: Compounds and compositions as protein kinase inhibitors . Patent WO 2011025927 A1

Title: Li Z, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44.

Related Products of of 1269440-17-6
Building Blocks More >
1271738-62-5
1271738-62-5
Mi-2
AA000WNT | MFCD22575021
127413-59-6
127413-59-6
1-(3-Bromo-5-nitrophenyl)ethanone
AA000WZ2 | MFCD20923634
127792-49-8
127792-49-8
2-Bromo-5-chlorophenylacetonitrile
AA000XCD | MFCD18390586
128008-30-0
128008-30-0
Indium(iii) trifluoromethanesulfonate
AA000XM9 | MFCD00144478
128276-50-6
128276-50-6
4,6-Dimethoxypyrimidine-2-carboxylic acid
AA000XV0 | MFCD03645365
1286734-85-7
1286734-85-7
6-Bromo-5-fluoro-1H-indazole
AA000Y7H | MFCD18089816
1289387-50-3
1289387-50-3
(6-Bromo-pyridin-3-ylmethyl)-cyclopropyl-amine hydrochloride
AA000YKW | MFCD18837145
1292317-54-4
1292317-54-4
2-((Tetrahydro-2H-pyran-4-yl)oxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
AA000YWF | MFCD22393670
1315281-29-8
1315281-29-8
1H-Imidazole, 2-chloro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
AA000Z8S | MFCD11100959
131713-50-3
131713-50-3
2,2-Dimethoxypropan-1-amine
AA000ZK4 | MFCD10698200
Submit
© 2017 AA BLOCKS, INC. All rights reserved.